Community

Stellantis is an underappreciated gem in an out-of-favor market. Recent layoffs at their Michigan plant unrelated to tariffs have only compounded the malaise brought on by recent whiplash trade policy changes.

Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and manufacturing vaccines for the disease at breakneck pace also happened to have bagged a historic windfall in exchange for its performance.

This is one of three major benefits the company brings to the table: As I just briefly explained, the company has a high-margin business model, as it does not incur drilling costs. The Permian is home to almost half of all onshore horizontal rigs in the United States.

MTN Nigeria Plc has delivered a remarkable turnaround in Q1 2025, with profit after tax surging by 134% year-on-year to ₦133.64 billion , a significant recovery from the ₦392.7 billion loss reported in Q1 2024 , firmly signaling the telecom giant’s return to profitability. Key Financial Highlights: Revenue: ₦1.057 trillion ▲ +40.5% YoY (Q1 2024: ₦753 billion) Profit After Tax: ₦133.64 billion ▲ +134% YoY EBITDA: Up 65.9%; EBITDA Margin: 46.6% ▲ +7.2 ppts Free Cash Flow: ₦209.9 billion ▼ -54.8%, impacted by accelerated capex Net FX Losses: ₦5.5 billion ▼ -99.2% (Q1 2024: ₦656.4 billion) Net Finance Costs: ₦134.5 billion ▼ -44% YoY Capex: ₦202.4 billion ▲ +159% YoY Operational Drivers and Strategic Execution MTN’s strong topline performance was fueled by a 51.5% surge in data revenue (₦529.4 billion) and 27.7% increase in voice revenue (₦407.4 billion).

Cadbury Nigeria Plc saw its market value surge by 21% in the equities segment of the Nigerian Exchange (NGX) over the past week, as investor sentiment turned optimistic in anticipation of the company’s Q1 2025 earnings release. The stock advanced from ₦22.00 to ₦26.60 , with over 1.34 million shares changing hands, amounting to ₦35.3 million in value.

Catalysts Most Immediate Catalyst (1–2 Years): Strong Oncology Portfolio Growth: AstraZeneca’s cancer drugs Tagrisso, Imfinzi, Enhertu, and Calquence continue gaining market share, driving double-digit revenue growth in oncology. Respiratory & Cardiovascular Expansion: New approvals and label expansions in Farxiga (diabetes/heart failure) and Tezspire (severe asthma) can drive meaningful sales upside.

U.S. jewelry sales advanced a tepid 1.3% in 2024, driven primarily by price increases as the number of units sold dropped 1.6%, according to industry analyst Edahn Golan of Tenoris. Yet, while American consumers largely hit the pause button on new jewelry purchases, the accessible-luxury jewelry brand Pandora posted 8% same-store sales growth in the U.S. last year.

EBIT-margin trajectory: Historical: 2.3 % → 3.6 % (FY 22/23) ​, down to – 2 % (FY 23/24) ​, back to 3 % in Q1 24/25 ​ Forecast: Gradual recovery to 4–6 % by FY 25/26, reaching 6–8 % by FY 29/30 Revenue growth: Historical: + 70 % (FY 22/23) ​, + 30 % (FY 23/24) ​, + 27 % (Q1 24/25) ​ Forecast: ~ 15 % CAGR over the next five years (FY 24/25–29/30) Five-year share-price goal: Current fair value: € 8.5–9.0 per share Five-year target: € 14–15 per share (≈ 1.9 bn EUR market cap) Enterprise value (EV) outlook (DCF-based): Revenues rising to ~ 1.8 bn EUR by FY 29/30 EBIT of ~ 145 m EUR (8 % margin) → NOPAT ~ 102 m EUR FCF margin ~ 5 % → ~ 90 m EUR FCF Terminal-value multiple: EV/FCF = 15 → TV ~ 1.35 bn EUR Discounted EV: ≈ 1.18 bn EUR + net cash 0.69 bn EUR → ≈ 1.87 bn EUR → ~ 14.8 EUR/share Top risks: execution delays, margin pressure from competition, raw-material cost swings, subsidy uncertainty, heavy capex needs Narrative Outlook Over the next five years, thyssenkrupp nucera is poised to leverage its unique position at the intersection of mature Chlor-Alkali expertise and rapid Green-Hydrogen adoption. After a transitional phase in FY 23/24 with negative margins driven by upfront investments, the company’s shift toward series-manufactured AWE modules and high-growth project backlog supports a steady margin recovery.

Full disclosure. I am a shareholder at the time of writing this.